• Loading stock data...
PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

Tony Allen by Tony Allen
April 26, 2019
in Medical
2 min read
76
0
Tikcro Technologies To Present Unique Properties of a Novel CTLA-4 Antibody at the AACR Annual Meeting 2019 in the U.S.

REHOVOT, Israel, March 14, 2019 /PRNewswire/ — Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage antibody immunotherapy company leveraging a novel mimitope approach for antibody generation, today announced that it will present a scientific poster featuring the unique properties of a novel CTLA-4 antibody at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held at the Georgia World Congress Center in Atlanta, GA on Friday, March 29, 2019 – Wednesday, April 3, 2019.

The poster titled “A CTLA4 antibody with enhanced properties” will feature TikAb, a full human CTLA-4 antibody, and in-vitro and in-vivo assay results with comparative data to the existing treatment will be presented.

Title: A CTLA-4 antibody with enhanced properties

Date: Tuesday, April 2, 2019

Time: 8:00am – 12:00pm ET

Session: Immune Checkpoints 1

Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 24

Additional abstract information is available here: https://www.abstractsonline.com/pp8/#!/6812/presentation/2667

About Tikcro Technologies


Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro’s website at www.tikcro.com.

SOURCE Tikcro Technologies Ltd.

Related Links

http://www.tikcro.com

Read More

Tony Allen

Tony Allen

Tony Allen received a bachelor’s degree in journalism from the University of South Florida in 2011, specializing in feature writing and reporting on sports and events.

Related Posts

Regeneron buy back shares from Sanofi
Medical

Regeneron to buy back $5 billion shares from Sanofi

May 25, 2020
132
A report reveals that China is deliberately faking the number of COVID-19 cases and deaths.
General

China is underreporting COVID-19 cases, U.S. intelligence community says

April 1, 2020
151
Around the world, the total number of confirmed coronavirus infection went beyond 600,000, with 28,964 fatalities as of the latest report.
Medical

17% of all confirmed COVID-19 cases in the world comes from the US

March 28, 2020
138
President Donald Trump signed a $2 trillion coronavirus relief bill on Friday
General

Trump signs $2 trillion coronavirus relief

March 28, 2020
121
General Motors and Ventec Life Systems are partnering to convert the GM Kokomo, Indiana ERC building for the production of Ventec ventilators in response to the COVID-19 pandemic.
General

GM announces the start of production of critical-care ventilators shortly after Trump’s tweets against CEO

March 27, 2020
132
Rep. Thomas Massie, R-Ky., tried to force a full yes or no vote on the measure, which could have delayed its passage by hours.
Finance

$2 trillion coronavirus stimulus package passed by the House amid efforts to delay voting by Massie

March 27, 2020
118
Currently Playing

Subscribe To Our Newsletter

Ad

PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2020 PublicWire.com

Navigate Site

  • About
  • #96576 (no title)
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • #370 (no title)

© Copyright 2020 PublicWire.com

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Public Wire Logo

Hello please subscribe to our newsletter to get up to date news weekly!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.